AIH patients who received everolimus (Certican; Novartis, Switzerland) therapy between 2014 and 2021 were retrospectively identified from the Pediatric Hepatology database of the Cliniques Universitaires Saint-Luc (Brussels, Belgium). The inclusion criteria were: diagnosis of definite AIH or ASC according to the ESPGHAN juvenile AIH/ASC scoring system (score ≥ 8, retrospectively applied), patients aged 0–18 at the time of everolimus introduction and pretransplant state (1 (link)). Everolimus was introduced in patients refractory to first-/second-line therapies or in patients who suffered from adverse events related to those medications. This research project was assessed and approved by the Biomedical Ethics Committee of the Université catholique de Louvain (Brussels, Belgium; no. 2020/04SEP/445).
Certican
Manufactured by Novartis
Sourced in Switzerland
Certican is a pharmaceutical product developed by Novartis. It is a medication used to prevent organ rejection in patients who have undergone solid organ transplantation. Certican works by inhibiting the activity of a protein called mTOR, which is involved in the growth and division of cells.
Automatically generated - may contain errors
Lab products found in correlation
Simulect, by Novartis (3 mentions)
Cellcept, by Roche (3 mentions)
Prograf, by Astellas Pharma (2 mentions)
Neoral, by Novartis (2 mentions)
Sandimmun, by Novartis (1 mentions)
Rapamune, by Pfizer (1 mentions)
Myfortic, by Novartis (1 mentions)
Sandimmun neoral, by Novartis (1 mentions)
Cyclosporine, by Novartis (1 mentions)
Tacrolimus, by Novartis (1 mentions)
Prograft, by Astellas Pharma (1 mentions)
Everolimus, by Novartis (1 mentions)
11 protocols using certican
1
Everolimus Therapy for Pediatric AIH
2
Immunosuppressive Regimen for Liver Transplantation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Immunosuppressive treatment included a regimen featuring a calcineurin inhibitor, cyclosporine (Sandimmun, Novartis Pharmaceuticals, Basel, Switzerland) or tacrolimus (Prograf, Astellas Pharma Inc., Tokyo, Japan) as a component of a double- or triple-drug cocktail (the other 2 drugs were prednisone and mycophenolate mofetil [Myrept, Chong Kun Dang Pharmaceutical Corp., Seoul, Korea]). An interleukin-2 receptor blocker (Simulect, Novartis Pharmaceuticals) was administered on the day of the operation and on postoperative day 4. Steroids were withdrawn 1 month after surgery, and mycophenolate mofetil was withdrawn 6 months after surgery. Only a low-dose calcineurin inhibitor was given after this time. The immunosuppressive protocol in the patients who underwent LT due to HCC did not differ from those used to treat benign diseases. When recurrence was detected during follow-up, the immunosuppressive agent was switched to everolimus (Certican, Novartis Pharmaceuticals), or a low trough level of the immunosuppressant was maintained.
3
Preparation of Immunosuppressant Drug Solutions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Voclosporin (Lupkynis™, Aurinia Pharmaceuticals Inc.), cyclosporin A (Neoral®, Novartis), tacrolimus (Prograf®, Astellas), mycophenolate mofetil (CellCept®, Roche) or everolimus (Certican®, Novartis) stock solutions were prepared by dissolving the pharmaceutical formulation of these drugs in dimethyl sulfoxide (DMSO). Placebo capsules and pure VCS powder (Aurinia Pharmaceuticals Inc.), Tacrolimus (PHR1809), cyclosporin A (30024) and mycophenolic acid (M5255) (all from Sigma-Aldrich) and remdesivir (RDV; HY-104077, MedChemExpress) were dissolved in DMSO and stored at −20°C as single-use aliquots. Remdesivir was used as a standard positive control in all experiments.
4
Lanreotide and Everolimus Combination Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Lanreotide 3 mg/kg was administered every 2 wk intramuscular (somatuline, gift from Ipsen Pharma; Merelbeke, Belgium). Everolimus oral solution 1 mg/kg per day (Certican®; gift from Novartis Pharma; Basel, Switzerland) was administered via the drinking water without further additives. Dosages were chosen based on previous published data[10 (link),12 (link),20 (link)]. We used black drinking bottles to ensure light protection in the EVR group. Drug solutions were freshly prepared every morning and adjusted to body weight and fluid intake once weekly.
5
Everolimus and Prednisolone in Stable Renal Transplant
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Clinical data from 97 stable renal transplant recipients treated with immunosuppressive duotherapy consisting of everolimus (Certican, Novartis) and prednisolone, participating in a prospective, open, randomized, multicenter study were studied from 6 to 24 months after transplantation.42 (link) During the first 6 months, patients were treated with an immunosuppressive regimen cyclosporine, prednisolone, and mycophenolate; thereafter, a scheduled biopsy was performed. Patients whose biopsy showed no sign of rejection were included. Subsequently, cyclosporine and mycophenolate were discontinued. Everolimus therapy was started at an oral dose of 3 mg b.i.d. and was supported by routine TDM based on AUC0–12 h. TDM was aimed at a target of 120 μg·h/l. Everolimus concentrations were obtained at steady state at regular clinical visits scheduled at 32, 52, 78, and 104 weeks after transplantation.
6
Evolution of Liver Transplant Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
During the study period (1996–2002), the transplant procedure, perioperative management, and immunosuppressive schedules changed according to technological advancements and scientific evidence. The University of Wisconsin (UW) perfusion solution was used until 2001, whereas Celsior® (IGL, Lissieu, France) was utilized thereafter. Bypass, or the classical technique, was standard until 2017. De novo immunosuppression consisted of a triple regimen of microemulsion cyclosporine (CyA) (Neoral®, Novartis, Origgio (VA), Italy), steroids (S), and azathioprine (AZA) until 1999; CyA, S, and mycophenolate mofetil (MMF) until 2001; and a quadruple regimen with anti-CD25 (basiliximab, Simulect®, Novartis, Origgio (VA), Italy) since 2002. The use of tacrolimus (TAC) was initiated at our institution in 1999 and has become the standard de novo calcineurin inhibitor since 2009. The use of everolimus (EVR) (Certican®, Novartis, Origgio (VA), Italy) began in 2005 in maintenance schedules and in 2008 in de novo regimens. From 2002 onward, anti-CMV prophylaxis was administered to recipients without acquired immunity (D+/R− and D−/R− combinations).
7
Immunosuppressive Regimens in Transplant
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The standard immunosuppressive regimen consists of TAC (Prograf or Advagraf, Astellas, Tokyo, Japan) with a trough level of 4–7 ng/mL, MPA (mycophenolate mofetil [MMF], Cellcept, Roche, Basel, Switzerland; or enteric-coated mycophenolate sodium, Myfortic, Novartis, Basel, Switzerland) 1000–1500 mg/day, and prednisolone (standard group). The MPA-sparing regimen comprised mTORi (sirolimus, Rapamune, Pfizer, New York, NY; or everolimus, Certican, Novartis, Basel, Switzerland) with a trough level of 5–10 ng/mL, low dose TAC (Prograf or Advagraf, Astellas, Tokyo, Japan) with a trough level of 2–4 ng/mL, and prednisolone (MPA-sparing group). The immunosuppressive regimens were not changed for at least 6 wk before entering the study and continued throughout the study period. The trough level of TAC, everolimus, and sirolimus were measured every 1–3 mo in every outpatient follow-up visit.
8
Preparation of Drug Solutions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Everolimus (Certican®, Novartis, Basilea, Switzerland), Sirolimus (Rapamune®, Pfizer, New York, USA) and Tacrolimus (Prograf, Astellas Pharma Inc., Tokio, Japan) were solved in DMSO (95.8, 91.5 and 80.4 μg/μl, respectively) in order to obtain working solution useful for the in vitro experiments. The drugs were diluted in ethanol (1 μg/μl) in order to obtain working solution useful for the in vivo experiments.
9
Immunosuppressive Regimens for Heart Transplant
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients received induction treatment with a regimen composed of antithymocyte globulin (ATG, Thymoglobulin ®Genzyme Corporation, Cambridge, MA) within 12 h before HTx and continued for up to 3 days. Patients were randomized within 5 days to either the EVR or the CNI group. The EVR group was treated with low‐exposure EVR (Certican; Novartis Pharma AG, Basel, Switzerland), low‐exposure cyclosporine (Sandimmun Neoral; Novartis Pharma AG), MMF, and CSs with cyclosporine withdrawal between 7 and 11 weeks post‐HTx. The CNI group was treated with cyclosporine, MMF, and CSs. Target trough levels and target doses of the treatment have been previously reported.19
10
Immunosuppressive Regimen for Lung Transplant
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Induction therapy consists of basiliximab (Simulect; Novartis Pharma, Basel, Switzerland). Maintenance immunosuppression consists of a calcineurin inhibitor (CNI)-based immunosuppressive regimen (trough levels 7-10) combined with prednisolone (0.05-0.15 mg/kg) and mycophenolate mofetil (CellCept; Roche, Basel, Switzerland). tacrolimus (Prograft; Astellas Pharma, Staines, UK) is the most commonly used CNI in our center. Upon significant decline of renal function patients receive a quadruple immunosuppressive scheme adding everolimus (Certican; Novartis Pharma, Basel, Switzerland) to enable CNI dose reduction (tacrolimus trough levels 3-4; everolimus trough levels 3-4). All patients receive Pneumocystis Jerovici prophylaxis (co-trimoxazole or inhaled pentamidine) and cytomegalovirus prophylaxis (valganciclovir) if applicable. Inhaled amphotericin B is used as fungal prophylaxis in the first months and azithromycin is used as standard CLAD prophylaxis in all patients unless patients experience side-effects.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!